{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:32:45Z","timestamp":1761237165966},"reference-count":35,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2003,5,2]],"date-time":"2003-05-02T00:00:00Z","timestamp":1051833600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2003,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> : There is a growing clinical trend to increase the daily dose of mesalazine, which leads to significant compliance issues associated with multiple dosings of current preparations.<\/jats:p><jats:p><jats:bold>Aim<\/jats:bold> : To examine the gastrointestinal performance and systemic exposure of a 1.5\u2003g sachet (micropellets) mesalazine formulation, compared with three enteric\u2010coated tablets (500\u2003mg each, Claversal).<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> : A randomized, two\u2010way, cross\u2010over pharmacoscintigraphic (scintigraphy plus pharmacokinetics) study and a two\u2010way, cross\u2010over, pharmacokinetic\u2010only study were performed in 24 healthy volunteers (12 subjects per investigation).<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> : The relative bioavailability of mesalazine was 92% comparing micropellets with Claversal tablets, and the cumulative urine excretion was <jats:italic>c<\/jats:italic>. 26% for both preparations, suggesting comparable systemic exposure for the two types of preparation. In the majority of subjects, drug release from the micropellet formulation occurred predominantly in the terminal ileum and ascending colon. The Claversal tablets disintegrated in comparable intestinal sites, albeit at slightly later time points than the micropellets, principally due to slower gastric emptying for the single\u2010unit formulation.<\/jats:p><jats:p><jats:bold>Conclusion<\/jats:bold> : The 1.5\u2003g micropellet formulation offers comparable delivery properties to the marketed tablets, but with greater convenience of dosing.<\/jats:p>","DOI":"10.1046\/j.1365-2036.2003.01558.x","type":"journal-article","created":{"date-parts":[[2004,12,19]],"date-time":"2004-12-19T09:08:45Z","timestamp":1103447325000},"page":"1153-1162","source":"Crossref","is-referenced-by-count":38,"title":["Combined scintigraphic and pharmacokinetic investigation of enteric\u2010coated mesalazine micropellets in healthy subjects"],"prefix":"10.1111","volume":"17","author":[{"given":"I. R.","family":"Wilding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. J.","family":"Tardif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Wray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,5,2]]},"reference":[{"key":"e_1_2_13_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1972134539"},{"key":"e_1_2_13_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198938040-00003"},{"key":"e_1_2_13_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140100-00003"},{"key":"e_1_2_13_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07284-7"},{"key":"e_1_2_13_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07499-8"},{"key":"e_1_2_13_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1993.tb00110.x"},{"key":"e_1_2_13_8_2","first-page":"645","volume-title":"Arzneimittelwirkungen, 8. Auflage","author":"Mutschler E","year":"2001"},{"key":"e_1_2_13_9_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0780119"},{"key":"e_1_2_13_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(89)91412-1"},{"key":"e_1_2_13_11_2","first-page":"479","article-title":"Intestinal metabolism and transport of 5\u2010aminosalicylate","volume":"27","author":"Zhou SY","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_13_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1990.tb00499.x"},{"key":"e_1_2_13_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.33.10.1338"},{"key":"e_1_2_13_14_2","first-page":"725","volume-title":"Inflammatory Bowel Disease: Current Status and Future Approach","author":"Klotz U","year":"1988"},{"key":"e_1_2_13_15_2","first-page":"3124","article-title":"Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties","volume":"46","author":"Tromm A","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_13_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059040-00016"},{"key":"e_1_2_13_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00501.x"},{"key":"e_1_2_13_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.3.410"},{"key":"e_1_2_13_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)90691-6"},{"key":"e_1_2_13_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1988.tb03301.x"},{"key":"e_1_2_13_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.28.2.196"},{"key":"e_1_2_13_22_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1017987229718"},{"key":"e_1_2_13_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1987.tb00627.x"},{"key":"e_1_2_13_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1984.tb02375.x"},{"key":"e_1_2_13_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198712243172603"},{"key":"e_1_2_13_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600810324"},{"key":"e_1_2_13_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.29.8.1035"},{"key":"e_1_2_13_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1989.tb00254.x"},{"key":"e_1_2_13_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1461-5347(99)00151-0"},{"issue":"5","key":"e_1_2_13_30_2","first-page":"20","article-title":"Formulations on trial.","volume":"3","author":"Nick C","year":"1996","journal-title":"Good Clinical Practice"},{"key":"e_1_2_13_31_2","doi-asserted-by":"publisher","DOI":"10.3109\/10611869409015908"},{"key":"e_1_2_13_32_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015849700421"},{"key":"e_1_2_13_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.33.10.1338"},{"key":"e_1_2_13_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.27.8.886"},{"key":"e_1_2_13_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127002762491280"},{"key":"e_1_2_13_36_2","unstructured":"The European Agency for Evaluation of Medical Products. CPMP\/ENP\/239\/95 Final Note for Guidance on the Clinical Requirements for Locally Applied Locally Acting Products Containing Known Constituents.London: Human Medicine Evaluation Unit in operation from June 1996."}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2003.01558.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2003.01558.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2003.01558.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T22:48:20Z","timestamp":1697237300000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2003.01558.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["10.1046\/j.1365-2036.2003.01558.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2003.01558.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5]]}}}